Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A04570 | Pages: 150 | Charts: 20 | Tables: 56 |
The global organ-tumor-on-a-chip market size was valued at $5,937.27 thousand in 2020, and is projected to reach $117,471.41 thousand by 2030, registering a CAGR of 34.3% from 2021 to 2030. Cancer is one of the leading causes of death, despite enormous efforts to explore cancer biology and develop anticancer therapies. The main challenges in cancer research are establishing an efficient tumor microenvironment in vitro and exploring efficient means for screening anticancer drugs to reveal the nature of cancer and develop treatments. Tumor-on-a-chip is a miniature cell culture device that simulates tumor cell tissue structure and functional units in vitro. Tumor-on-a-chip can be used to simulate tumor growth and expansion, angiogenesis, and progression from early to advanced lesions involving epithelial–mesenchymal transition (EMT), tumor cell invasion and metastasis.
[COVIDIMPACTSTATEMENT]
Organ-on-a-chip systems are based on the use of microfluidics to construct tissue models. Tumor-on-a-chip systems have emerged by using cancer-derived cells and related extracellular matrix (ECMs) in tissue-specific structures to replace healthy cells. Therefore, the main processing technology of tumor-on-a-chip systems is the same as that of organ-on-a-chip systems.
Get more information on this report : Request Sample Pages
There are several key elements in fabricating an integrated organ-on-a-chip, including a microfluidic system, 2D/3D microtissue culturing, stimulus-loading components, and sensors for monitoring and readout of the results. The emerging tumor-on-a-chip platforms integrating 3D cell culture, microfluidic technology, and tissue engineering have successfully mimicked the pivotal structural and functional characteristics of the in vivo tumor microenvironment.
A variety of techniques have been adopted to fabricate tumor-on-a-chip devices, among which the most widely employed are photolithography, replica molding, soft lithography, microcontact printing and bioprinting technology. With the development of materials and manufacturing techniques, such as microfluidics and microprinting, combined with stem cell technology, 3D human tissue-like models known as organoids and spheroids are generated. They can be used in human development research, disease progression, and treatment as well as to develop personalized drug methods. Organoids are 3D cell culture models that can self-organize into complex organ-like tissues. To create biomimetic 3D tumor models that better encapsulate pathologic processes, several important factors in the tumor microenvironment must be considered, including oxygen tension, which is a key regulator of cellular behavior. In contrast to the tumor growth microenvironment in vivo, tumor models in vitro are usually under atmospheric oxygen conditions, which are not representative of the conditions in vivo.
A variety of human-derived in vitro tumor-on-a-chip models have been developed for studying various characteristics associated with tumor progression, such as growth, angiogenesis, metastasis, and drug response. By combining advanced microfabrication techniques, such as photolithography, soft lithography and bioprinting, with microfluidic and tissue engineering techniques, tumor chips can ideally reproduce specific key aspects of the tumor microenvironment, such as biochemical gradients and niche factors, dynamic cell–cell and cell–matrix interactions, and complex tissue structures comprised of tumor and stromal cells. Since the tumor-on-a-chip system is usually composed of cells from a single organ, its recombination ability is limited. To solve this problem, researchers developed multiorgan-on-a-chip systems to evaluate the efficacy and off-target toxicity of anticancer therapeutics.
The COVID-19 outbreak has impacted the global organ-tumor-on-a-chip market negatively. The COVID-19 pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns, which impacted reliable supply of sufficient human cells or a supply at cost-effective prices, which harmed the business results of operations The extent to which COVID-19 will impact the future developments is highly uncertain and cannot be predicted with confidence, including the rise of vaccine-resistant variants, duration of the outbreak, travel bans, restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns.
The organ-tumor-on-a-chip market is segmented on the basis of type, and region. By type, the market is segmented into lung tumor-on-a-chip, bone marrow tumor-on-a-chip, brain tumor-on-a-chip, breast tumor-on-a-chip, urinary system tumor-on-a-chip, intestine tumor-on-a-chip, and liver tumor-on-a-chip.
Region wise, the organ-tumor-on-a-chip market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By type, the lung tumor-on-a-chip segment was the highest revenue generator in 2020, and is anticipated to continue this trend in the future, owing to rising prevalence in lung cancer cases.
[TYPEGRAPH]
Get more information on this report : Request Sample Pages
By region, North America accounted for the largest organ-tumor-on-a-chip market share in 2020 and is expected to retain its dominance throughout the forecast period, owing to rise in demand for organ-tumor-on-chips in drug screening, especially in the U.S., increase in number of key market players, and research centers in the region.
The major companies profiled in this report include Axosim Technologies LLC, Beonchip S. L., BioIVT LLC, Emulate Inc., InSphero AG, Mimetas B.V., Nortis, Inc., and Organovo Holdings, Inc.
[REGIONGRAPH]
Get more information on this report : Request Sample Pages
Key Benefits For Stakeholders
Key Market Segments
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top Player Positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increasing Prevalence of Cancer
3.5.1.2.Rising Demand for Personalized Medicine
3.5.2.Restraints
3.5.2.1.Complexity of organ-tumor-on-a-chip
3.5.2.2.Incompatibility of currently used material in manufacturing chip
3.5.3.Opportunity
3.5.3.1.Novel Techniques in oncology research
3.6.Impact Analysis of COVID-19 on the Organ-tumor-on-a-chip Market
CHAPTER 4:ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Lung Tumor-on-a-Chip
4.2.1.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Bone Marrow Tumor-on-a-chip
4.3.1.Market size and forecast
4.3.2.Market analysis, by country
4.4.Brain Tumor-on-a-chip
4.4.1.Market size and forecast
4.4.2.Market analysis, by country
4.5.Breast Tumor-on-a-chip
4.5.1.Market size and forecast
4.5.2.Market analysis, by country
4.6.Urinary System Tumor-on-a-chip
4.6.1.Market size and forecast
4.6.2.Market analysis, by country
4.7.Intestine Tumor-on-a-chip
4.7.1.Market size and forecast
4.7.2.Market analysis, by country
4.8.Liver Tumor-on-a-chip
4.8.1.Market size and forecast
4.8.2.Market analysis, by country
CHAPTER 5:ORGAN-TUMOR-ON-A-CHIP, BY REGION
5.1.Overview
5.1.1.Market size and forecast
5.2.North America
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by country
5.2.2.1.U.S. organ-tumor-on-a-chip market, by Type
5.2.2.2.Canada organ-tumor-on-a-chip market, by type
5.2.2.3.Mexico organ-tumor-on-a-chip market, by type
5.2.3.North America market size and forecast, by type
5.3.Europe
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by country
5.3.2.1.Germany organ-tumor-on-a-chip market, by type
5.3.2.2.France organ-tumor-on-a-chip market, by type
5.3.2.4.UK organ-tumor-on-a-chip market, by type
5.3.2.5.Italy organ-tumor-on-a-chip market, by type
5.3.2.7.Spain organ-tumor-on-a-chip market, by type
5.3.2.8.Rest of Europe organ-tumor-on-a-chip market, by type
5.3.3.Europe market size and forecast, by type
5.4.Asia-Pacific
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by country
5.4.2.1.Japan organ-tumor-on-a-chip market, by type
5.4.2.2.China organ-tumor-on-a-chip market, by type
5.4.2.3.Australia organ-tumor-on-a-chip market, by type
5.4.2.5.India organ-tumor-on-a-chip market, by type
5.4.2.6.South Korea organ-tumor-on-a-chip market, by type
5.4.2.7.Rest of Asia-Pacific organ-tumor-on-a-chip market, by type
5.4.3.Asia-Pacific market size and forecast, by type
5.5.LAMEA
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by country
5.5.2.1.Brazil organ-tumor-on-a-chip market, by type
5.5.2.2.Saudi Arabia organ-tumor-on-a-chip market, by type
5.5.2.3.South Africa organ-tumor-on-a-chip market, by type
5.5.2.4.Rest of LAMEA organ-tumor-on-a-chip market, by type
5.5.3.LAMEA market size and forecast, by type
CHAPTER 6:COMPANY PROFILES
6.1.AXOSIM TECHNOLOGIES LLC
6.1.1.Company overview
6.1.2.Company snapshot
6.1.3.Product portfolio
6.1.5.Key strategic moves and development
6.2.BEONCHIP S.L.
6.2.1.Company overview
6.2.2.Company snapshot
6.2.3.Product portfolio
6.3.BIOIVT LLC
6.3.1.Company overview
6.3.2.Company snapshot
6.3.3.Operating business segments
6.3.4.Product portfolio
6.3.5.Key strategic moves and development
6.4.EMULATE INC.
6.4.1.Company overview
6.4.2.Company snapshot
6.4.3.Product portfolio
6.5.INSPHERO AG
6.5.1.Company overview
6.5.2.Company snapshot
6.5.3.Operating business segments
6.5.4.Product Portfolio
6.6.MIMETAS B.V.
6.6.1.Company overview
6.6.2.Company snapshot
6.6.3.Operating business segments
6.6.4.Product portfolio
6.6.5.Key strategic moves and development
6.7.NORTIS, INC.
6.7.1.Company overview
6.7.2.Company snapshot
6.7.3.Operating business segments
6.7.4.Product portfolio
6.8.ORGANOVO HOLDINGS, INC.
6.8.1.Company overview
6.8.2.Company snapshot
6.8.3.Operating business segments
6.8.4.Product portfolio
6.8.5.Business performance
LIST OF TABLES
TABLE 01.ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020–2030 ($THOUSAND)
TABLE 02.ORGAN-TUMOR-ON-A-CHIP MARKET FOR LUNG TUMOR-ON-A-CHIP, BY REGION, 2020–2030 ($THOUSAND)
TABLE 03.ORGAN-TUMOR-ON-A-CHIP MARKET FOR BONE MARROW TUMOR-ON-A-CHIP, BY REGION, 2020–2030 ($THOUSAND)
TABLE 04.ORGAN-TUMOR-ON-A-CHIP MARKET FOR BRAIN TUMOR-ON-A-CHIP, BY REGION, 2020–2030 ($THOUSAND)
TABLE 05.ORGAN-TUMOR-ON-A-CHIP MARKET FOR BREAST TUMOR-ON-A-CHIP, BY REGION, 2020–2030 ($THOUSAND)
TABLE 06.ORGAN-TUMOR-ON-A-CHIP MARKET FOR URINARY SYSTEM TUMOR-ON-A-CHIP, BY REGION, 2020–2030 ($THOUSAND)
TABLE 07.ORGAN-TUMOR-ON-A-CHIP MARKET FOR INTESTINE TUMOR-ON-A-CHIP, BY REGION, 2020–2030 ($THOUSAND)
TABLE 08.ORGAN-TUMOR-ON-A-CHIP MARKET FOR LIVER TUMOR-ON-A-CHIP, BY REGION, 2020–2030 ($THOUSAND)
TABLE 09.ORGAN-TUMOR-ON-A-CHIP MARKET, BY REGION, 2020-2030 ($THOUSAND)
TABLE 10.NORTH AMERICA ORGAN-TUMOR-ON-A-CHIP MARKET, BY COUNTRY, 2020-2030 ($THOUSAND)
TABLE 11.U.S. ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 12.CANADA ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 13.MEXICO ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 14.NORTH AMERICA ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 15.EUROPE ORGAN-TUMOR-ON-A-CHIP MARKET, BY COUNTRY, 2020-2030 ($THOUSAND)
TABLE 16.GERMANY ORGAN-TUMOR-ON-A-CHIP MARKET, BY TECHNOLOGY, 2020-2030 ($THOUSAND)
TABLE 17.FRANCE ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 18.UK ORGAN-TUMOR-ON-A-CHIP MARKET, BY TECHNOLOGY, 2020-2030 ($THOUSAND)
TABLE 19.ITALY ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 20.SPAIN ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 21.REST OF EUROPE ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 22.EUROPE ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 23.ASIA-PACIFIC ORGAN-TUMOR-ON-A-CHIP MARKET, BY COUNTRY, 2020-2030 ($THOUSAND)
TABLE 24.JAPAN ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 25.CHINA ORGAN-TUMOR-ON-A-CHIP MARKET, BY TECHNOLOGY, 2020-2030 ($THOUSAND)
TABLE 26.AUSTRALIA ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 27.INDIA ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 28.SOUTH KOREA ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 29.REST OF ASIA-PACIFIC ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 30.ASIA-PACIFIC ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 31.LAMEA ORGAN-TUMOR-ON-A-CHIP MARKET, BY COUNTRY, 2020-2030 ($THOUSAND)
TABLE 32.BRAZIL ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 33.SAUDI ARABIA ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 34.SOUTH AFRICA ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 35.REST OF LAMEA ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 36.LAMEA ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE, 2020-2030 ($THOUSAND)
TABLE 37.AXOSIM: COMPANY SNAPSHOT
TABLE 38.AXOSIM: PRODUCT PORTFOLIO
TABLE 39.AXOSIM: KEY DEVELOPMENTS
TABLE 40.BEONCHIP: COMPANY SNAPSHOT
TABLE 41.BEONCHIP: PRODUCT PORTFOLIO
TABLE 42.BIOIVT: COMPANY SNAPSHOT
TABLE 43.BIOIVT: PRODUCT PORTFOLIO
TABLE 44.BIOIVT: PRODUCT PORTFOLIO
TABLE 45.BIOIVT: KEY DEVELOPMENTS
TABLE 46.EMULATE, INC: COMPANY SNAPSHOT
TABLE 47.EMULATE: PRODUCT PORTFOLIO
TABLE 48.INSPHERO AG: COMPANY SNAPSHOT
TABLE 49.INSPHERO AG: PORTFOLIO
TABLE 50.MIMETAS: COMPANY SNAPSHOT
TABLE 51.MIMETAS.: PRODUCT PORTFOLIO
TABLE 52.MIMETAS: KEY DEVELOPMENTS
TABLE 53.NORTIS, INC.: COMPANY SNAPSHOT
TABLE 54.NORTIS: PRODUCT PORTFOLIO
TABLE 55.ORGANOVO HOLDINGS: COMPANY SNAPSHOT
TABLE 56.ORGANOVO HOLDINGS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.ORGAN-TUMOR-ON-A-CHIP MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS IN ORGAN-TUMOR-ON-A-CHIP MARKET
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021*
FIGURE 06.HIGH BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.MODERATE THREAT OF NEW ENTRANTS
FIGURE 09.MODERATE THREAT OF SUBSTITUTION
FIGURE 10.HIGH COMPETITIVE RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.MARKET DYNAMICS: ORGAN-TUMOR-ON-A-CHIP MARKET
FIGURE 13.COMPARATIVE ANALYSIS OF ORGAN-TUMOR-ON-A-CHIP MARKET FOR LUNG TUMOR-ON-A-CHIP, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF ORGAN-TUMOR-ON-A-CHIP MARKET FOR BONE MARROW TUMOR-ON-A-CHIP, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF ORGAN-TUMOR-ON-A-CHIP MARKET FOR BRAIN TUMOR-ON-A-CHIP, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF ORGAN-TUMOR-ON-A-CHIP MARKET FOR BREAST TUMOR-ON-A-CHIP, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF ORGAN-TUMOR-ON-A-CHIP MARKET FOR URINARY SYSTEM TUMOR-ON-A-CHIP, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF ORGAN-TUMOR-ON-A-CHIP MARKET FOR INTESTINE TUMOR-ON-A-CHIP, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF ORGAN-TUMOR-ON-A-CHIP MARKET FOR LIVER TUMOR-ON-A-CHIP, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.ORGANOVO HOLDINGS: NET SALES, 2018–2020 ($MILLION)